Aligos Therapeutics, Inc.
Aligos Therapeutics Inc. (Nasdaq Capital Market: ALGS) is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections. The company's pipeline includes three potential best-in-class drug candidates targeting chronic hepatitis B… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Aligos Therapeutics, Inc. does
In the company’s own words
Aligos Therapeutics Inc. (Nasdaq Capital Market: ALGS) is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections. The company's pipeline includes three potential best-in-class drug candidates targeting chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis and obesity, and coronavirus infections.
The company's lead program, pevifoscorvir sodium, is a capsid assembly modulator designed for chronic HBV infection. In Phase 1 clinical trials spanning up to 96 weeks, pevifoscorvir sodium demonstrated multi-log10 reductions in viral antigens and substantial HBV DNA suppression compared to standard nucleos(t)ide analog treatments. The company is currently advancing this candidate in the Phase 2 B-Supreme study, a randomized, double-blind, active-controlled trial evaluating safety and efficacy in approximately 200 untreated subjects with chronic HBV infection, with topline data expected in 2027.
ALG-055009, a thyroid hormone receptor beta agonist, is being developed for MASH and obesity. Phase 2a data demonstrated statistically significant reductions in liver fat content at 12 weeks in subjects with presumed MASH. Preclinical data suggests synergistic fat mass loss when combined with incretin receptor agonists. The company is evaluating various funding options for continued development, including potential out-licensing.
ALG-097558 is a ritonavir-free pan-coronavirus protease inhibitor showing threefold greater potency than approved coronavirus protease inhibitors in cell-based assays. Phase 1 clinical studies demonstrated favorable tolerability and pharmacokinetics without requiring ritonavir boosting. The candidate is currently in Phase 2 clinical studies sponsored by AGILE University of Liverpool in standard and high-risk COVID-19 patients.
The company's management team brings decades of combined experience in drug discovery and development for viral infections and liver diseases, with involvement in the discovery and development of multiple commercially successful drugs. Aligos maintains internal capabilities in small molecule and oligonucleotide chemistry, with dedicated chemistry, manufacturing, and control teams supporting contract development and manufacturing organizations. The company's website is www.aligos.com.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1799448
- SIC
- 2836
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Aligos Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Aligos Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Aligos Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Aligos Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Aligos Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”